101. New Insights into Monoclonal B-Cell Lymphocytosis
- Author
-
Kalpadakis, Christina, Pangalis, Gerassimos A., Sachanas, Sotirios, Vassilakopoulos, Theodoros P., Kyriakaki, Stavroula, Korkolopoulou, Penelope, Koulieris, Efstathios, Moschogiannis, Maria, Yiakoumis, Xanthi, Tsirkinidis, Pantelis, Kyrtsonis, Marie-Christine, Levidou, Georgia, Papadaki, Helen A., Panayiotidis, Panayiotis, and Angelopoulou, Maria K.
- Subjects
Article Subject ,immune system diseases ,hemic and lymphatic diseases ,chemical and pharmacologic phenomena ,bacterial infections and mycoses - Abstract
Monoclonal B-cell lymphocytosis (MBL) is a premalignant condition characterized by the presence of less than 5000/μL circulating clonal B cells in otherwise healthy individuals. Three subcategories have been identified according to the immunophenotypic features: CLL-like, CD5(+) atypical, and CD5(−) MBL. CLL-like MBL is by far the most frequent and best studied category and further divided in low-count [LC] and high-count [HC] MBL, based on a cutoff value of 500/μL clonal B cells. LC-MBL typically remains stable and probably does not represent a truly premalignant condition, but rather an age-related immune senescence. On the other hand, HC-MBL is closely related to CLL-Rai0, bearing similar immunogenetic profile, and is associated with an annual risk of progression to CLL requiring therapy at a rate of 1.1%. Currently there are no reproducible factors for evaluating the risk of progression to CLL. CD5(−) MBL is characterized by an immunophenotype consistent with marginal zone origin and displays many similarities with marginal zone lymphomas (MZL), mainly the splenic MZL. The cutoff value of 5000/μL clonal B cells cannot probably be applied in CD5(−) MBL, requiring a new definition to describe those cases.
- Published
- 2014
- Full Text
- View/download PDF